Additive Value of [<sup>68</sup>Ga]Ga-RM26 PET/CT to [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study
Lymph node staging in prostate cancer is crucial for treatment and prognosis, yet [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT has limited sensitivity in detecting pelvic lymph node metastasis (PLNM). [<sup>68</sup>Ga]Ga-RM26 PET/CT, targeting the gastrin-releasing peptide receptor, complements [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT in assessing primary tumor extension and aggressiveness. However, its role in detecting PLNM and complementing [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT remains underexplored. <b>Methods:</b> This prospective study enrolled newly diagnosed yet untreated prostate cancer patients who underwent [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT, followed by radical prostatectomy and extended pelvic lymph node dissection. The primary objective was to evaluate the diagnostic performance of both PET/CT modalities in detecting PLNM. <b>Results:</b> In total, 68 patients were enrolled, with a 30.9% (21/68) pathologic PLNM rate. In patient-based analysis, [<sup>68</sup>Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.43 and 0.94, respectively, compared with 0.52 and 0.89 for [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. [<sup>68</sup>Ga]Ga-RM26 PET/CT detected additional PLNMs in 50% (5/10) of patients that were missed by [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. The combined use of [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT resulted in sensitivity of 0.76 and specificity of 0.85. In total, 1,049 lymph nodes were dissected, including 991 normal and 58 positive nodes. In lesion-based analysis, [<sup>68</sup>Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.38 and 0.99, respectively, compared with 0.5 and 0.99 for [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. [<sup>68</sup>Ga]Ga-RM26 PET/CT identified 41.4% (12/29) of pathologic positive nodes missed by [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. The combined [<sup>68</sup>Ga]Ga-RM26 and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT demonstrated sensitivity of 0.71 and specificity of 0.99. <b>Conclusion:</b> In dual-target imaging, [<sup>68</sup>Ga]Ga-RM26 PET/CT identified additional PLNMs. The combination of [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT achieved higher diagnostic sensitivity with minimal loss of specificity.
Authors
- Xiaomei Gao (ORCID: https://orcid.org/0000-0002-9247-5825)
- Yongxiang Tang (ORCID: https://orcid.org/0000-0003-3987-8702)
- Shuo Hu (ORCID: https://orcid.org/0000-0003-0998-8943)
- Yi Cai (ORCID: https://orcid.org/0000-0001-7773-2064)
- Wei Tang
- Lin Qi (ORCID: https://orcid.org/0000-0002-4587-8226)
- Ye Zhang (ORCID: https://orcid.org/0009-0000-4883-8097)
- Minfeng Chen
Institutions
- Central South University (CN)
- National Health and Family Planning Commission (CN)
- National Clinical Research (US)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2025-03-20
- DOI
- https://doi.org/10.2967/jnumed.124.269189
- Citations
- 3
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- National Natural Science Foundation of China
- Central South University
- China Postdoctoral Science Foundation
- Xiangya Hospital, Central South University
- Fundamental Research Funds for the Central Universities